Aptar Pharma Pays Pharmaxis US $5m to Acquire Orbital Technology

4th Aug 22

Release Date: 04/08/2022 5:12pm

  • Drug delivery leader Aptar Pharma exercises option for a worldwide license to the “Orbital” technology for $US2.5m and a subsequent option for an outright purchase of the technology for a further US$2.5 million.
  • Aptar Pharma’s decision supported by the potential for safe and convenient administration of high dose treatments to the lungs
  • Pharmaxis retains rights to inhaled mannitol products delivered via the Orbital inhaler

Read full media release - pdf

Categories: News and Media